Amgen Stock Edges Near Analyst Targets on Solid Fundamentals

Amgen stock has reached a level close to analyst targets, according to recent data. The company's shares have been trading near the average target price of $387.69 per share, compiled in mid-September 2026. This suggests that the market has already priced in much of Amgen's expected earnings and dividend story.

The stock has shown solid fundamentals, with recent quarters reporting earnings that beat market expectations. This is a key factor contributing to the company's strong performance, as highlighted by financial portals. The shares have been trading near $385.65 on Nasdaq, leaving limited upside from the latest close.

Amgen's dividend growth record also adds value for income-oriented investors. The company has consistently increased its payout over time and has a strong track record compared to peers in the sector. Despite this, the current price still leaves room for additional upside if the company continues to deliver above-consensus results and maintains its dividend growth trajectory.

As of September 21, 2026, Amgen's market capitalization stood at around $208.45 billion, illustrating its position as one of the larger constituents in the global biotechnology space. The company's strong fundamentals, combined with its solid dividend record, make it an attractive investment opportunity for those interested in large-cap healthcare names.